The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Diwakar Davar
Christine SpencerThe Multiple Myeloma Hub was delighted to speak to Christine Spencer, Parker Institute for Cancer Immunotherapy, San Francisco, US, and Diwakar Davar, University of Pennsylvania Medical Center, Pittsburgh, US, during the American Association for Cancer Research (AACR) Virtual Annual Meeting I.
The microbiome and its effects on the immune system
In this animated video, Christine Spencer and Diwakar Davar describe the microbiome and its effects on the immune system. The pair begin by explaining the role of the microbiome, the concept of immunosurveillance, and how the composition of the intestinal microbiota could affect the response to cancer therapy. They describe the past and present research investigating how the microbiome can be altered to support the efficacy of immunotherapies, with a focus on checkpoint inhibitors. Finally, they discuss how the microbiome can reduce immune reactions, such as graft-versus-host disease, and immunotherapy-related toxicities.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content